{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:45:54Z","timestamp":1793454354161,"version":"4.5.0"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tofacitinib is a targeted JAK inhibitor used to treat rheumatoid arthritis. Despite some recent safety concerns, it is considered effective and safe with appropriate patient selection. Between May 2015 and May 2024, data were retrospectively analyzed from 112 patients with a diagnosis of RA in a tertiary care hospital who had received tofacitinib for at least 1\u2009month, with or without prior biologic DMARDs. The mean disease duration was 12\u2009years, and the median duration of tofacitinib use was 32.5\u2009months. The <jats:italic>p<\/jats:italic>\u2010value for all disease activity parameters evaluated for effectiveness between the 1st\u2010 and 3rd\u2010month visits was &lt;0.001, except CRP (<jats:italic>p<\/jats:italic>\u2009=\u20090.097). Adverse events occurred in 15 (13.4%) patients, with an incidence rate of 4.54 per 100 patient\u2010years. Observed were one myocardial infarction (0.3\/100 patient\u2010years), two pulmonary embolisms (0.6\/100 patient\u2010years), three herpes zoster (HZ) (0.9\/100 patient\u2010years), and one basal cell carcinoma (BCC) (0.3\/100 patient\u2010years). Median drug\u2010free survival was 68 (95% CI: 54.8\u201381.2) months. The drug was discontinued in 28 (25%) patients due to ineffectiveness and in 13 (11.6%) due to side effects. A significant difference in drug survival rates was observed between patients who had not previously used bDMARDs and those who had received at least one bDMARD before tofacitinib (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Drug survival was 46.35\u2009months in the prior bDMARD group and 71.09\u2009months in the bDMARD\u2010naive group. This study found significant reductions in disease activity indices at 3 and 6\u2009months after starting tofacitinib, with sustained effectiveness. Although adverse event rates were somewhat higher than reported in the literature, tofacitinib can be used effectively and safely in appropriate patient populations for RA treatment.<\/jats:p>","DOI":"10.1111\/cts.70084","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T13:54:25Z","timestamp":1731938065000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real\u2010world data"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-1293","authenticated-orcid":false,"given":"Ali","family":"Ekin","sequence":"first","affiliation":[{"name":"Division of Rheumatology Bursa Uludag University Faculty of Medicine  Bursa Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-1855","authenticated-orcid":false,"given":"Salim","family":"Misirci","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Bursa Uludag University Faculty of Medicine  Bursa Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6461-2220","authenticated-orcid":false,"given":"Selin","family":"\u0130ldemir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Bursa Uludag University Faculty of Medicine  Bursa Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-4157","authenticated-orcid":false,"given":"Belk\u0131s Nihan","family":"Coskun","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Bursa Uludag University Faculty of Medicine  Bursa Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-1986","authenticated-orcid":false,"given":"Burcu","family":"Yagiz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Bursa Uludag University Faculty of Medicine  Bursa Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-2670","authenticated-orcid":false,"given":"Ediz","family":"Dalkilic","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Bursa Uludag University Faculty of Medicine  Bursa Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7054-5351","authenticated-orcid":false,"given":"Yavuz","family":"Pehlivan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Bursa Uludag University Faculty of Medicine  Bursa Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2022.01028"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S138677"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0835-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S322086"},{"issue":"3","key":"e_1_2_10_10_1","first-page":"485","article-title":"Real\u2010world experience with tofacitinib for the treatment of rheumatoid arthritis","volume":"37","author":"Caporali R","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32240"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/do2uxu"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkac090"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177057"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9341-17"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216761"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11232"},{"issue":"10","key":"e_1_2_10_20_1","article-title":"Post\u2010marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data","volume":"69","author":"Mimori T","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:19:01Z","timestamp":1732605541000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/cts.70084"],"URL":"https:\/\/doi.org\/10.1111\/cts.70084","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70084"}}